share_log

Stephens & Co. Downgrades Lifecore Biomedical to Equal-Weight, Lowers Price Target to $2

Stephens & Co. Downgrades Lifecore Biomedical to Equal-Weight, Lowers Price Target to $2

Stephens & Co.将Lifecore Biomedical的评级下调至同等权重,将目标价下调至
Benzinga ·  2023/03/20 08:21

Stephens & Co. analyst Jacob Johnson downgrades Lifecore Biomedical (NASDAQ:LFCR) from Overweight to Equal-Weight and lowers the price target from $11 to $2.

Stephens & Co. 分析师雅各布·约翰逊将Lifecore Biomedical(纳斯达克股票代码:LFCR)的评级从增持下调至同等权重,并将目标股价从11美元下调至2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发